top of page

Portfolio Companies

Facts & Figures

1

Initial Portfolio Company

3

Major Unmet Need Indications Being Studied

4

Molecules In Development

Potential Revenue Generation

~$5BN

Companies

Skiaphos
Hematology

Therapeutic Area | Hematology


Lead Indication    | AML

Pre-Clin
IND
Phase I
Phase II
Phase III
Lead asset is an oral dual target ENL-AF9(MLLT1/3) & FLT3 Inhibitor with cellular activity across multiple AML genotypes and the ability to combine with standard-of-care agents
Learn more
bottom of page